Orthhocell的神经修复产品Remplir获得林业发展局批准进入美国市场,价值16亿美元。 Orthocell's nerve repair product, Remplir, gains FDA approval for the US market, valued at $1.6 billion.

Orthocell Ltd已获得林业发展局批准在美国市场上推出其神经修复产品Remplir。 Orthocell Ltd has received FDA approval to launch its nerve repair product, Remplir, in the US market. 用于神经修复手术的科兰根包装将在珀斯制造,在美国分发,这标志着该公司在价值16亿美元的市场上迈出了一大步。 The collagen wrap, used in nerve repair surgery, will be manufactured in Perth and distributed in the US, marking a significant step for the company in a market valued at $1.6 billion. 产品的批准和空运的便捷性突出了Orthocell的顺利进入战略。 The product's approval and ease of transportation by air freight highlight a smooth entry strategy for Orthocell.